公开(公告)号：US20200000821A1

公开(公告)日：2020-01-02

申请号：US16288615

申请日：2019-02-28

Applicant: Pfizer Inc.

Inventor： Patricia Ann BASFORD ,  Anthony Michael CAMPETA ,  Adam GILLMORE ,  Matthew Cameron JONES ,  Eleftherios KOUGOULOS ,  Suman LUTHRA ,  Robert WALTON

IPC: A61K31/55 ,  C07D487/06 ,  C07C57/145 ,  C07C309/19 ,  A61K45/06

Abstract: The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.